NCT04659161: A trial that was reported late by Karuna Therapeutics
This trial has reported, although it was 156 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04659161 |
|---|---|
| Title | A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adults With DSM-5 Schizophrenia |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 16, 2020 |
| Completion date | May 24, 2022 |
| Required reporting date | May 24, 2023, midnight |
| Actual reporting date | Oct. 27, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 156 |